

AMENDMENTS TO THE CLAIMS

This listing replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (Canceled)
2. (Currently Amended) An extracorporeal adsorption method for removing harmful substances responsible of inducing sepsis caused by Gram-negative or Gram-positive bacteria in a mammal, ~~said extracorporeal adsorption method being effected by an adsorption column assembly, said adsorption column assembly comprising a column and an adsorption medium in the form of particles, the sedimented volume of said particles being at the most 80% of the volume of the column, said particles being characterised by carrying an affinity specific molecule with a specific affinity for:~~
 - i) ~~the LPS portion of said Gram-negative bacteria, and/or~~
 - ii) ~~Gram-positive bacteria or harmful substances derived from said Gram-positive bacteria,~~

wherein said method comprising comprises treating blood obtained from said mammal by passing the blood through the an adsorption column assembly at such a flow rate that a fluidised bed of the particles is formed and the harmful substances are removed from the blood by binding of the harmful substances to the affinity specific molecules, thereby retaining them in the column, and

wherein said adsorption column assembly comprises a column and an adsorption medium in the form of particles, the sedimented volume of said particles being at the most 80% of the volume of the column, said particles being characterised by carrying an affinity specific molecule with a specific affinity for the LPS portion of said Gram-negative bacteria, and/or ii) Gram-positive bacteria or harmful substances derived from said Gram-positive bacteria, and/or ii) Gram-positive bacteria or harmful substances derived from said Gram-positive bacteria.
3. (Canceled)

4. (Currently Amended) ~~A~~ **The** method according to claim 2, wherein the adsorption column assembly is adapted for fluidised bed adsorption, ~~in particular stabilised fluidised bed adsorption.~~
5. (Currently Amended) ~~A~~ **The** method according to claim 2, wherein the particles have a density of at least 1.3 g/ml and a mean diameter in the range of 5-1000 μm , ~~such as a density of at least 1.5 g/ml and a mean diameter in the range of 5-300 μm , preferably a density of at least 1.8 g/ml and a mean diameter in the range of 5-150 μm , and most preferred a density of more than 2.5 g/ml and a mean diameter in the range of 5-75 μm .~~
6. (Currently Amended) ~~A~~ **The** method according to claim 2, wherein the mammal is a human being.
7. (Currently Amended) ~~A~~ **The** The method according to claim 2, wherein the affinity specific molecule is selected from the group consisting of immunoglobulins, peptides, oligonucleotides, receptor proteins, antibiotics, and lectins.
8. (Currently Amended) ~~A~~ **The** method according to claim 2, wherein two or more different affinity specific molecules are present on particles within the adsorption medium.
9. (Currently Amended) ~~A~~ **The** method according to claim 6, wherein the affinity specific molecules are selected from immunoglobulins.
10. (Currently Amended) ~~A~~ **The** method according to claim 2, wherein the affinity specific molecule is Polymyxin B.
11. (Currently Amended) ~~A~~ **The** method according to claim 2, wherein the affinity specific molecule is selected from the group consisting of a Toll-like receptor, ~~most preferably~~ TLR4, ~~or~~ binding fragments ~~thereof or of~~ **TLR4**, multimeric arrangements ~~thereof of~~ **TLR4**, CD14, MD2, TLR2 and LBP, and any combination thereof.

12. (Currently Amended) ~~A~~ The method according to claim 2, wherein the sedimented volume of the particles is at the most 70% of the volume of the column, ~~such as at the most 60% of the volume of the column, e.g. at the most 50% of the volume of the column.~~

13. (Canceled)

14. (Canceled)

15. (Currently Amended) The method according to claim 27, wherein the flow rate of the blood through the column assembly is such that expansion ratio of the fluidised bed is at least 1.3, ~~such as at least 1.5.~~

16. (Previously Presented) The method according to claim 27, wherein the steps (a), (b) and (c) are preceded by a initial step by which a substance is first injected into the blood stream of the mammal.

17. (Previously Presented) The method according to claim 27, wherein the mammal is a human being.

18. (Currently Amended) The method according to claim 27, wherein the particles have a density of at least 1.3 g/ml and a mean diameter in the range of 5-1000 μm , ~~such as a density of at least 1.5 g/ml and a mean diameter in the range of 5-300 μm , preferably a density of at least 1.8 g/ml and a mean diameter in the range of 5-150 μm , and most preferred a density of more than 2.5 g/ml and a mean diameter in the range of 5-75 μm .~~

19. (Currently Amended) ~~A~~ The method according to claim 27, wherein the stabilised fluidised bed is placed in line with a switch capable of being activated when a blood substance reaches a pre-set value, said blood substance is monitored by a device, said device is placed in line with the blood circulation, said device sending the activating signal to the switch when said value is reached.

20. (Previously Presented) The method according to claim 27, wherein the affinity specific molecule is selected from the group consisting of immunoglobulins, peptides, oligonucleotides, receptor proteins, antibiotics, and lectins.
21. (Previously Presented) The method according to claim 27, wherein two or more different affinity specific molecules are present on particles within the adsorption medium.
22. (Previously Presented) The method according to claim 27, wherein the affinity specific molecules are selected from immunoglobulins.
23. (Previously Presented) The method according to claim 27, wherein the affinity specific molecule is Polymyxin B.
24. (Currently Amended) ~~A~~ **The** method according to claim 27, wherein the affinity specific molecule is selected from the group consisting of a Toll-like receptor, ~~most preferably~~ TLR4, ~~or~~ binding fragments ~~thereof or~~ **of TLR4**, multimeric arrangements ~~thereof of TLR4~~, CD14, MD2, TLR2 and LBP, and any combination thereof.
25. (Currently Amended) The method according to claim 27, wherein the sedimented volume of the particles is at the most 70% of the volume of the column, ~~such as at the most 60% of the volume of the column, e.g. at the most 50% of the volume of the column..~~
26. (Previously Presented) The method according to claim 27, wherein the flow rate is such that stabilised fluidised bed of the particles is formed.
27. (Currently Amended) A method for the treatment of sepsis caused by Gram-negative or Gram-positive bacteria in a mammal by extracorporeal adsorption, ~~said extracorporeal adsorption being effected by an adsorption column assembly, said adsorption column assembly comprising a column and an adsorption medium in the form of particles, the sedimented volume of said particles being at the most 80% of the volume of the column, said particles being characterised by carrying an affinity specific molecule with a specific affinity for:~~

~~i) the LPS portion of said Gram-negative bacteria, and/or~~
~~ii) Gram-positive bacteria or harmful substances derived from said Gram-~~
~~positive~~

~~bacteria,~~

said method comprising the steps of:

- a) obtaining blood from said mammal,
- b) treating the obtained blood by passing the blood through ~~the~~ an adsorption column assembly at such a flow rate that a fluidised bed of the particles is formed, ~~and~~
- c) removing the harmful substances from the blood by binding of the harmful substances to the affinity specific molecules, thereby retaining them in the column, and then

d) reinfusing the treated blood into the same mammal,
wherein said adsorption column assembly comprises a column and an adsorption medium in the form of particles, the sedimented volume of said particles being at the most 80% of the volume of the column, said particles being characterised by carrying an affinity specific molecule with a specific affinity for (i) the LPS portion of said Gram-negative bacteria, and/or (ii) Gram-positive bacteria or harmful substances derived from said Gram-positive bacteria.

28. (Canceled)